Louis Cheng, CEO of Taiwanese firm Leadgene Biomedical, introduces the company’s expertise in antibody technologies, his ambitious internationalization plans, and comments on the vital role that companies like Leadgene have to play in more effective COVID-19 diagnostics.
Given our status as a raw materials developer, we see an opportunity to expand our offering during this pandemic. Our agility and ability to re-orientate our direction quickly have enabled Leadgene to adapt to the new situation
